Medtronic

Stryker

Transforming neurological care with innovation

Neurostimulation Tech

Inspire Medical Systems, Inc. is a medical technology company that specializes in developing minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its flagship product, the Inspire system, is a proprietary neurostimulation technology approved by the FDA to treat moderate to severe OSA. The Inspire device is implanted surgically and controlled by the patient with a remote. It works by delivering mild stimulation to the hypoglossal nerve, gently moving the tongue forward and keeping the airway open during sleep.
As of December 2023, Inspire Medical Systems had treated over 60,000 patients with its Inspire therapy. The company reported revenue of USD 624.8 million for the full year 2023, representing a 53% increase over the previous year. In the first quarter of 2024, Inspire's revenue grew by 28% year-over-year, reaching USD 164 million, driven by increased market penetration, expansion into new territories, and greater awareness of its therapy among physicians and patients.
In June 2023, the FDA granted Inspire an expanded indication, increasing the upper limit of the Apnea Hypopnea Index (AHI) to 100 events per hour from 65 and raising the body mass index (BMI) warning in the labeling to 40 from 32. This expansion allows Inspire to treat patients with more severe OSA who previously had limited treatment options.
By the end of the first quarter of 2024, Inspire had 1,246 US medical centers providing its therapy and operated in 298 US sales territories. The company plans to continue its rapid expansion, projecting the activation of 52 to 56 new US centers and the addition of 12 to 14 new US sales territories per quarter for the remainder of 2024.

SetPoint Medical is a clinical-stage healthcare company developing a novel neuroimmune modulation platform to treat chronic, inflammation-mediated autoimmune diseases. The company's core technology involves a miniaturized stimulation device surgically placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure. Once implanted, the device delivers precise vagus nerve stimulation on a preset schedule, activating anti-inflammatory and immune-restorative pathways to treat conditions like rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS).
SetPoint Medical's initial focus is on rheumatoid arthritis, a debilitating autoimmune condition affecting over 1.5 million Americans and costing nearly USD 30 billion annually to manage with existing immunosuppressive therapies and biologics. The company believes its approach could offer a potentially less immunosuppressive treatment option. SetPoint Medical is currently evaluating its RA treatment in the RESET-RA pivotal trial, a multicenter, double-blind, randomized, sham-controlled study. As of January 2023, the first patient was enrolled in Stage two of the trial.
The FDA granted SetPoint Medical's device Breakthrough Device Designation for RA patients who have an incomplete response or intolerance to multiple biologic drugs. In March 2024, the company also received Breakthrough Device Designation from the FDA for using its platform to treat relapsing-remitting multiple sclerosis (RRMS), an autoimmune disorder affecting nearly 1 million Americans. SetPoint Medical is the first to initiate a clinical trial evaluating this neuroimmune modulation approach for RRMS.
Key customers and partnerships
SetPoint Medical secured an USD 80 million preferred stock financing in January 2023, co-led by new investors Norwest Venture Partners and Viking Global Investors, along with participation from Gilmartin Capital and existing investors. The financing will support the RESET-RA trial completion, FDA submissions, and early RA indication commercialization. As part of the financing, Dr. Zack Scott from Norwest joined SetPoint Medical's board of directors.
In March 2024, SetPoint Medical was accepted into the FDA's Total Product lifecycle (TPLC) Advisory Program Pilot to expedite the development and patient access of its neuroimmune modulation platform for RRMS treatment. This program facilitates earlier interactions with providers, payors, patients, and strategic advice from the FDA's Center for Devices and Radiological Health.

Saluda Medical is a global medical device company revolutionizing the field of neuromodulation with an advanced portfolio of therapies driven by closed-loop technologies designed to treat debilitating neurological disorders. The company's flagship product, the Evoke System, is a groundbreaking spinal cord stimulation (SCS) system that automatically adjusts therapy based on precise measurements of the nerves' response to stimulation over 4 million times per day. This "closed-loop" technology maintains optimal pain inhibition, providing continually optimized therapy tailored to each patient's unique spinal cord activation.
The Evoke System received FDA approval in March 2022 for treating chronic intractable pain of the trunk and/or limbs, including pain associated with failed back surgery syndrome, intractable low back pain, and leg pain. The approval was based on the pivotal EVOKE study, the first double-blind randomized controlled trial for an SCS system, which demonstrated the Evoke System's superiority over open-loop SCS in pain relief and improvements in quality of life measures like disability, mood, sleep, and health-related quality of life. Notably, the 24-month results published in JAMA Neurology in January 2024 showed durable clinical outcomes with no explants due to loss of efficacy.
After a limited commercial release in 2022, Saluda Medical expanded the Evoke System's availability in 2023, propelled by a USD 150 million equity financing round led by Wellington Management, Fidelity Management & Research Company, and TPG in April 2023. The company also redomiciled as Saluda Medical Inc., a Delaware corporation, that year. In chronic pain, a debilitating condition affecting over 19 million Americans, the Evoke System offers an innovative approach by automatically self-adjusting therapy to optimize each patient's spinal cord activation.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. The company’s technology integrates with over 200 diabetes and biometric devices worldwide, offering the largest compatibility among connected care platforms.Glooko’s FDA-approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices. The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app.In <a href="https://sp-edge.com/updates/9200?industryIds=22">March 2022</a>, Glooko acquired Paris-based DIABNEXT, a diabetes care platform, and rebranded it as Glooko XT for the French market. Furthermore, in <a href="https://sp-edge.com/updates/8154">January 2022</a>, Glooko acquired Berlin-based xbird, a medical AI company developing solutions for predicting health risks and supporting diabetes management through personalized interventions.Key customers and partnershipsAs of October 2024, Glooko had partnered with more than 8,000 clinics and served 4.4 million users with diabetes across 30 countries.&nbsp;The company has established several key partners, including 1) <a href="https://www.hedia.com/hedia-and-glooko-reveal-new-global-partnership/">Hedia</a> to integrate Hedia's insulin dosing algorithm into Glooko's platforms (June 2023), 2) <a href="https://sp-edge.com/updates/25233">Better Therapeutics</a> to integrate Better Therapeutics' AspyreRx into Glooko's platform (January 2024), and 3) Sanofi to integrate Sanofi's SoloSmart device into the Glooko platform (February 2023).

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko’s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices.The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries.As of March 2022, the company had acquired two companies: 1) <a href="https://sp-edge.com/updates/8154">xbird </a>, a German AI-backed medical company, and 2) French diabetes care platform <a href="https://sp-edge.com/updates/9200?industryIds=22">DIABNEXT </a>as part of its planned global expansion drive. The integration of xbird’s Just In Time Adaptive Intervention technology will enhance Glooko’s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which allow the company to scale its operations into more regions and expand its remote patient monitoring services.As of <a href="https://sp-edge.com/updates/34688">October 2024</a>, more than 4.4 million people worldwide with diabetes have used the Glooko platform.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

CathWorks is a medical technology company that has developed the FFRangio System, an innovative solution for diagnosing and assessing coronary artery disease (CAD). Founded in 2013, the company is headquartered in Kfar Saba, Israel, with additional operations in Irvine, California. The FFRangio System combines artificial intelligence and advanced computational science to obtain quick and reliable fractional flow reserve (FFR) values from routine angiograms. Unlike traditional FFR methods, which require invasive pressure wires and drug stimulation, the FFRangio System provides a non-invasive, wire-free, and drug-free intraprocedural physiological assessment for the entire coronary tree in just five minutes. This technology eliminates the need for invasive pressure wires and hyperemic agents, potentially improving patient comfort and streamlining the diagnostic process. Clinical data published in the Journal of the American College of Cardiology: Cardiovascular Interventions demonstrated a diagnostic accuracy of 93%, sensitivity of 91%, and specificity of 94%. In July 2022, CathWorks entered into a strategic partnership with Medtronic, which included a USD 75 million investment and co-promotion agreement for the FFRangio System in the US, Europe, and Japan.

From counting steps to saving lives and beyond

Wearable Tech

Earlens Corporation, now rebranded as Virsono Hearing Centers as of April 2024, is a provider of innovative hearing solutions and telehealth-enabled audiology services. Their flagship product, the Earlens Hearing System, utilizes a unique technology that involves placing a custom-fitted lens directly on the eardrum. This lens gently vibrates the eardrum across the full frequency range, transmitting high-fidelity audio signals from the ear tip.
The Earlens Hearing System offers several key advantages over traditional hearing aids. It provides a broader bandwidth, up to 10,000 Hz, allowing for enhanced audibility of high-frequency sounds crucial for speech understanding. Additionally, the direct vibration of the eardrum results in exceptional sound quality, closely resembling natural hearing.
Clinical research has demonstrated the superiority of the Earlens system in various aspects of auditory perception. Studies have shown significant improvements in speech recognition, consonant recognition, and word-final /s/ detection when compared to conventional hearing aids. Furthermore, the extended audible bandwidth has been proven to enhance speech understanding in complex, noisy environments.
The Earlens Hearing System is suitable for individuals aged 18 and above with mild to severe sensorineural hearing loss. It offers personalized settings through a user-friendly app, allowing wearers to fine-tune the device according to their preferences and unique hearing needs. In April 2024, Earlens Corporation announced the acquisition of its hearing centers by a new entity, Virsono Hearing Centers, as part of its commitment to broadening hearing care treatment and meeting evolving patient needs.

Avation Medical is pioneering new platforms for wearable nerve stimulation systems. They believe empowering patients to be in control of their therapies will allow for more personalized and custom care. That's why at Avation Medical, they are re‑imagining neuromodulation by developing patient‑centric solutions based on powerful, proven, smart technologies. Avation Medical transforms the neuromodulation market to elevate care for patients with chronic conditions.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize pci therapy decisions and elevate coronary angiography from visual assessment to an objective FFRangio-based decision-making tool for physicians.

Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design and integration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.

Titan Medical Inc., a development stage company, engages in the design and development of SPORT single-port robotic surgical system for application in minimally invasive surgery (MIS).

Rockley is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke. Building on its technology, the Company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. In 2008, the company completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011 the Company completed a 300 patients RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.

Triple Jump Medical is a developer of an insulin pump intended to treat diabetic patients.

BioProtect Ltd. is an international medical device startup. It is primarily engaged in to the business of developing and commercializing biodegradable balloon spacers for the protection of normal tissue during cancer radiation therapy. The company's current focus in the growing radiotherapy spacers market, where its ProSpace balloon spacer (CE marked) has shown superior efficacy and safety in protecting the rectum during radiation therapy for prostate cancer. The company's technology platform of biodegradable implantable balloons suits a wide range of applications for unmet clinical needs. BioProtect was founded in the year 2004 and headquartered in Israel, with subsidiaries in Germany and US.

Sinovation Medical focuses on developing medical robot technology and intelligent medical product innovation.

Saluda Medical was established in 2013 with the goal of commercializing four years of research from NICTA, Australia’s information communications technology center of excellence. The company's team is made up of engineers, clinicians, and seasoned professionals with experience in bringing medical technologies to life.

MC10, Inc. extends human capabilities through virtually invisible and conformal electronics. They reshape rigid, conventional electronics into thin, flexible devices that can stretch, bend and twist seamlessly with their bodies and the natural world. It combines breakthrough technology with innovative engineering to develop products that advance the quality of life. The company's end-to-end system designed for In-Home and In-Clinic Study Execution.  Its proprietary BioStamp system wearable health tech creates comfortable, discreet sensors that can be applied anywhere on the body for targeted data collection. With location-specific sensing capabilities, BioStamp sensors are able to retrieve real-world data about muscle activation and movement.

Nanos Medical is engaged in the research and development, manufacturing and sales of disposable medical devices. The company's current core products are concentrated in the cardiovascular and ENT fields.

Yosemite Clinic is a full-service clinic providing convenient walk-in medical services in a state-of-the-art environment in Central Pudong. They offer family medicine, internal medicine, surgery, orthopedics (sports medicine), dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, anesthesiology, rehabilitation medicine, medical imaging, laboratory, pharmacy and more. Their onsite facilities and equipment include CT, X-ray, Ultrasound, Laboratory and Operating Rooms. Their doctors come from China and across the world, enabling us to serve you in many languages including, English, Japanese, Malay, Mandarin Chinese and Cantonese.

AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-based procedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California.

Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.

Mazor Robotics is a spine surgery innovator—inspiring the art of surgery with guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and OR staff. Renaissance, Mazor Robotics’ new guidance system, is transforming spine surgery from freehand procedures to highly-accurate, state-of-the-art procedures that raise the standard of care with better clinical outcomes. The company was founded by Professor Moshe Shoham and Mr. Eli Zehavi in 2001 and is headquartered in Cesarea, Israel.

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Glooko develops a remote patient-monitoring platform to identify at-risk patients with diabetes. It integrates with diabetes devices, fitness wearables, and activity trackers to allow data capture and provide reports and analytics that aim to drive behavior change and outcomes. The platform not only syncs diabetes data but also enhances communication between individuals with diabetes and their healthcare providers, leading to improved health outcomes. Glooko is available on both Android and iOS, providing users with the ability to track their diabetes data on their smartphones.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process.  The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Forerunner Medical (Shanghai) Co., Ltd., founded in 2009, is a developer and manufacturer of innovative medical devices for minimally invasive treatment . With valuable resources of domestic clinical data and the basement of US tech development, coupled wonderful team in the field of low- temperature radiofrequency ablation and minimally invasive medical equipment manufacturing, they focus on localized development of China clinical use and maximum the needs of domestic and global.  They put the quality and safety performance of their products in the first place. Combining fist-class experiments, perfect production equipment and professional technology, their products have excellent competitive advantage by high-performance, graceful appearance and convenience of using.

Inspire Medical Systems is a developer of innovative, implantable neurostimulation technologies to treat Obstructive Sleep Apnea (OSA). Utilizing well-established technologies from the fields of cardiac pacing and neurostimulation, Inspire has developed a proprietary Upper Airway Stimulation (UAS) therapy for patients who suffer from OSA.

MD Start is an incubator and fund dedicated to medical technologies.  MD Start creates, develops, and operates medical projects, turning them into new companies with both strategic and hands-on approaches, in order to bring them to investment stage and commercial development.

Ortho Kinematics is a spine diagnostics company, provides spine motion analysis and diagnostic services.  The company provides information to spine clinicians to assist them in diagnosing and treating back and neck pain. Its solution includes KineGraph Vertebral Motion Analyzer, an automated functional diagnostic test for the spine that uses fluoroscopy to capture the spine in motion, producing patient-specific graphs of the kinematics for each vertebral level.  The company was founded in 2006 and is based in Austin, Texas.

DreaMed Diabetes is a medical device, SaaS company providing personalized diabetes treatment optimization solutions. The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Eversince, DreaMed Diabetes has been vigorously working on decision support tools in the diabetes management space and became the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps. We offer a clinically proven decision support system for insulin titration in type 1 diabetes patients. Our Advisor Pro software was created by diabetes professionals and is based on real-world experience, turbo-charged by artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. By frequent titration changes and online monitoring, we allow patients better treatment thus by lowering their A1C levels and risk for complications. Using the Advisor Pro physicians and nurses can provide true patient-centered care and everyone can receive the same top-level of treatment – wherever they are and whoever their caregiver is.

Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA.

PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clear vision at all distances. Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s. PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between.   It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does. For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again.

CardioInsight is commercializing a revolutionary technology called Electrocardiographic Mapping (ECM) that non-invasively generates 3D images of the electrical activity of the heart.  The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure.   ECM non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3-D anatomical data obtained from CT scans. The CardioInsight system reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. The ability of ECM to generate accurate images of the heart's electrical activity and its potential to guide therapy in both cardiac arrhythmias and congestive heart failure has been demonstrated in over 260 patient studies sponsored by the Company.

Intersect ENT Inc. (formerly Sinexus) is a medical device company pioneering novel therapies for Ear, Nose, and Throat surgeons to utilize in providing improved treatment for their patients. The company was founded in 2003 by Don Eaton and is headquartered in Menlo Park, California, United States.

Mitralign is a venture backed privately held company located in a suburb of Boston, MA. The company is developing an innovative catheter based technology for percutaneous treatment of functional mitral regurgitation. The novel Mitralign system emulates surgical annuloplasty as it delivers a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.  Mitralign is funded by top tier venture capitalists and has two major cardiovascular device companies as investors.

Visualase, Inc. was founded in 2005 as a spin-off from BioTex, Inc., the original developer and current manufacturer of the Visualase technology. Visualase, Inc. is currently a privately held company located in Houston, Texas.

Functional Neuromodulation, a medical technology company, develops neuromodulation technologies for cognitive and memory disorders. It offers deep brain stimulation therapies for Alzheimer's disease and mild cognitive impairment. The company was founded in 2010 and is based in Toronto, Canada.

Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

PhysioSonics (Seattle, WA) a development-stage device company focused on ultrasound imaging to monitor blood flow in the brain.

CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

GI Dynamics, Inc., a medical device company, develops therapies for the treatment of type 2 diabetes and related metabolic diseases in the United States. Its products also include EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. The company was founded in 2003 and is based in Lexington, Massachusetts.

Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures.  Salientâ€™s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the companyâ€™s bipolar AQUAMANTYSÂ® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology.  Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATIONÂ® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss.  Salientâ€™s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.

Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. Our proprietary microchip-based implant can store and release precise doses of drugs over months and years. The implant, which is placed under the skin by a trained physician during a simple office procedure using local anesthesia, can be wirelessly activated or deactivated by a physician or patient, without requiring removal. In addition, physicians can wirelessly modify the frequency or dose of the drug to meet the individual needs of each patient.

Ardian is a privately held, clinical-stage medical device company that develops catheter-based therapies for hypertension treatment and related conditions. It develops a catheter system that uses radio-frequency energy to “deactivate” sympathetic nerves in the kidneys, lowering blood pressure. The company's flagship product, the Symplicity Catheter System, addresses uncontrolled hypertension through renal denervation, or ablation of the nerves lining the renal arteries. It has received the CE (Conformité Européene) mark and Australia's Therapeutic Goods Administration (TGA) listing but is not yet approved by the U.S. Food and Drug Administration (FDA).

Arbor Surgical Technologies, Inc. located in Irvine and Portola Valley, CA  (USA), is a privately held cardiovascular medical device company focused on  the heart valve replacement market.  Founded in 2002 by Dr. Thomas J. Fogarty  and noted heart valve designer, Ernie Lane, Arbor is developing multiple  technologies that have the potential to deliver significant clinical benefit  to patients worldwide.  Arbor intends to develop and commercialize its core  technologies in varying combinations, giving the company the opportunity to  create a portfolio of product offerings.  Currently in clinical trials, Arbor  is developing a tissue heart valve family of products designed for improved  performance over existing valves and compatible implantation tools that  simplify and speed valve replacement surgery.

REVA Medical develops bio resorbable polymers for vascular applications, to restore patient health for life through the application of biomaterials in the development and sale of implantable medical devices.

NanoCor Therapeutics is a biotechnology company founded to create a viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF).  The company was spun off from AsklÃªpios BioPharmaceutical, Inc. in November 2005.  NanoCorâ€™s initial focus is the commercial development of a non-invasive treatment for CHF. NanoCorâ€™s therapeutic is comprised of the delivery of a proprietary gene developed at the Massachusetts General Hospital and the University of Cincinnati. The gene will be delivered with AskBioâ€™s proprietary Biological NanoParticle (BNPâ„¢) and the Self-Complementary Vector technologies, which are derived from human adeno-associated virus vectors (rAAV).

InnerPulse, Inc. develops technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias. It offers invasive treatment that enables physicians to implant the life-saving Percutaneous Implantable Cardioverter Defibrillator within the patient's vascular system. InnerPulse, Inc. was formerly known as Interventional Rhythm Management, Inc.

Axial Biotech is a privately held, venture-backed company founded in 2002 by a group of internationally recognized spine surgeons and geneticists. Axial Biotech is focused on developing and commercializing genetic tests and treatment solutions for spinal disorders.

Medusa revolutionized EMS patient care documentation in the late 1990's with the introduction of Siren ePCR Suite. Today, they continue to drive ePCR technology to improve patient care with innovative solutions like hospital notification systems and real-time data communications. Siren is a complete software solution that enables paramedics to chart patient care and share information in real-time, easily manage ePCR workflow and analyze patient data. Ultimately, Siren helps agencies realize significant clinical and operational benefits to improve performance and quality.

Vascular Architects, Inc. designs, develops, manufactures and markets devices used in the treatment of vascular stenoses, occlusions and non-vascular obstructions. A key area of emphasis is the treatment of peripheral vascular disease, which manifests itself as a reduction or loss of blood flow due to the narrowing or closing of arteries.  Vascular Architects was founded in October 1997 by Thomas J. Fogarty, M.D. Dr Fogarty is an internationally renowned surgeon, professor, inventor and entrepreneur who has founded or cofounded more than 25 start-up companies that develop innovative medical devices. He has authored or coauthored over 150 professional articles, is a member of 29 professional societies, and is an inventor on more than 65 U.S. patents.  Their founder and management team form a highly experienced group of technical, clinical and business personnel. Key opinion leaders in the interventional and vascular surgery communities have been recruited to serve on the Vascular Architects' Scientific Advisory Board.

Percardia is a medical device company that develops therapies for the treatment of coronary artery disease. Its products include VSTENT myocardial implant, a balloon-deployable stainless steel stent.  Percardia was founded in 1998 and is based in Merrimack, New Hampshire.

The MindGuard team offers a unique blend of scientific and engineering expertise. The company know-how integrates the fields of mechanical engineering, blood flow dynamics and blood cell biology with cardiology, neurology and invasive radiology. World opinion leaders are active participants on the multidiscipline International Advisory Board purposed to further company endeavors.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Transvascular develops products for the treatment of coronary and peripheral vascular disease and congestive heart failure.

Odin Medical Technologies develops, manufactures and commercializes Intraoperative MRI systems designed for use by the neurosurgeon in standard ORs. The compact, open PoleStar N-10* is a real-time imaging and navigation system utilized during all stages of brain surgery. The unit offers the neurosurgeon the differentiation capabilities of MRI without restricting the freedom of the surgical team to access the patient. The Companyï¿½s mission is to improve neurosurgical interventions with minimally invasive procedures. *PoleStar N-10 is FDA cleared for intraoperative MR imaging in a conventional O.R.

Spinal Dynamics develops neuro-surgical devices for the replacement of spinal disks. The company's Bryan Cervical Disc System is an implanted prosthesis designed to replace and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs. It features a shock-absorbing elastomer that is intended to cushion the vertebrae and allow movement of the head and neck and is designed to replace the disc that is removed from the patient in cervical spine surgery.

Complient Corporation, based in Cleveland, is the nation's premier  provider of AED programs and actively manages hundreds of corporate and  government AED programs representing more than 3,000 AED devices.  Complient  trains lay people to save lives and prepares them to respond to commonplace  medical emergencies.  To date, over 250,000 individuals have been trained on  AED operation and CPR by its 150 dedicated full- and part-time trainers on  staff covering all 50 states in the United States.  Since its inception in  1997, over $50 million in equity venture capital has been invested to develop  Complient's web-based technology infrastructure and AED program management  service business.  For more information, visit www.complient.com.

Medtronic provides healthcare technology solutions for complex and challenging conditions. They deliver treatments and therapies for the lungs, brain, dental, diabetes, ENT, heart, gastrointestinal, orthopedic, urinary, and women's health. The company's technologies and therapies treat 70 different medical conditions and include patient monitoring systems, robotic surgery, insulin pumps, cardiac devices, and more. Medtronic delivers innovative technologies that change people's lives through to its extensive knowledge, insatiable curiosity, and desire to assist everyone in need.

<div> Medtronic (NYSE: MDT) is a medical technology company that designs, develops, and manufactures a wide range of medical devices. The company's operational headquarters are in Minneapolis, Minnesota, while its legal headquarters are in Ireland. Medtronic has been listed on NYSE since 1980. Medtronic was <a href="https://www.proclinical.com/blogs/2022-9/the-top-10-medical-device-companies-in-the-world-in-2022"> the largest medical device company in the world by revenue </a> in 2022, having generated USD 31.7 billion during the year. Medtronic's four operating segments primarily develop, manufacture, distribute, and sell device-based medical therapies and services. The Cardiovascular Portfolio is made up of the Cardiac Rhythm &amp; Heart Failure, Structural Heart &amp; Aortic, and Coronary &amp; Peripheral Vascular divisions. The Medical Surgical Portfolio is made up of the Surgical Innovations &amp; Respiratory, Gastrointestinal, and Renal divisions. The Neuroscience Portfolio is made up of the Cranial &amp; Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. The Diabetes Operating Unit develops, manufactures, and markets products and services for the management of Types 1 and 2 diabetes. The US market accounted for ~51% of Medtronic&rsquo;s total revenue in 2022, followed by non-US developed markets (~32%) and emerging markets (~17%). In October 2022, Medtronic announced its intention to spin off its Patient Monitoring and Respiratory Interventions businesses into a new entity. In the same announcement, Medtronic stated that its future capital allocation strategy would focus on higher-growth markets and revenue acceleration. Medtronic targets to reach the net-zero status by 2045.&nbsp; </div>

Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

Functional Nutrition

Providers of tailored dietary recommendations based on an individual's genetics and lifestyle for optimal wellness and disease prevention. This also includes calorie-counting apps that assist with weight loss and management

Designers of tailored dietary plans to address root causes of chronic diseases and symptom management

Companies that develop and offer supplements and nutraceuticals focused on enhancing health, addressing nutrition deficiencies and supporting overall wellness

Companies that provide personalized food services, including medically tailored meals and a marketplace for diverse dietary products to meet individual needs

Companies that offer virtual consultations from dietitians and nutritionists offering guidance via personalized nutrition plans, lifestyle and dietary assessments, and a focus on long-term health and wellness

INCUMBENTS_PRESENT

<div>
 
 Medtronic has purchased Fortimedix Surgical, a Netherlands-based manufacturer of surgical instruments, for an undisclosed amount to boost its surgical and endoscopy portfolio. 
 Fortimedix Surgical is known for articulating instruments utilized in endoscopic, minimally-invasive, single-port, multi-port, and robotic surgeries. Its technology finds use in soft tissue robotics and flexible robotics. 
 
</div>

Medtronic

Featured Industries

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless